Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs State Street SPDR S&P Biotech ETF — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $4.21, while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTZ | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $27.92 | $169.55 |
52-Week Low | $3.63 | $93.43 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $4.04, up 8.46% in the last 24 hours, but technical indicators signal a bearish trend with moving averages and ADX strongly bearish. The stock lacks disclosed financial ratios, suggesting limited fundamental data availability. Recent news highlights ETFs betting against related stocks, indicating negative sentiment in its sector.
The outlook is cautious due to bearish technicals and sparse fundamentals. Risks include market volatility and competitive pressures, with no clear catalysts for upside. Investors should seek updated financial filings for a clearer assessment.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
